The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.

The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.

Seeking to evolve the way it educates and engages with healthcare professionals, Novartis is using digital technology to enhance the quality, transparency and reach of its interactions with the medical community.

Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.

Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges

RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.